Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 5Uveal Melanoma 2Neoplasms 2Neoplasm Metastasis 1Diabetes Mellitus, Insulin-Dependent, 12 1

Interventions

Ipilimumab 17tremelimumab 9Nivolumab 9durvalumab 8pembrolizumab 6Paclitaxel 5Carboplatin 4Capecitabine 4Bevacizumab 4lenvatinib 3spartalizumab 2balstilimab 2Radiotherapy 2Radiation 2Pemetrexed 2Oxaliplatin 2Doxorubicin 2Docetaxel 2Cisplatin 2CTLA-4 Antigen 2Blood Specimen Collection 2trastuzumab deruxtecan 1tilsotolimod 1tebentafusp 1relatlimab 1poly ICLC 1osimertinib 1folfirinox 1eribulin 1envafolimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × Monophenol Monooxygenase × Clear all
NCT00028431 2014-05-22

Novel Adjuvants for Peptide-Based Melanoma Vaccines

University of Southern California

Phase 1 Completed
19 enrolled
Dermatologic

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡